SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Outset Medical, Inc. - OM
NEW YORK, Aug. 1, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Outset Medical, Inc. ("Outset" or the "Company") (NASDAQ: OM). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
The investigation concerns whether Outset and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On June 13, 2022, Outset issued a press release announcing, among other things, guidance for the second quarter of 2022. In the press release, Outset also announced that it "implemented a shipment hold on the distribution of its Tablo Hemodialysis System for home use pending the Food and Drug Administration's ('FDA') review and clearance of a 510(k) the Company submitted for changes made since the device's original March 2020 clearance."
On this news, Outset's stock price fell $6.95 per share, or 34.05%, to close at $13.46 per share on June 14, 2022.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com
CONTACT:
Robert S. Willoughby
Pomerantz LLP
[email protected]
888-476-6529 ext. 7980
SOURCE Pomerantz LLP
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article